Orphan designation: N-[(1S)-1-(4-Tert-butylphenyl) ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide Treatment of erythromelalgia, 23/02/2026 Positive | European Federation of Internal Medicine

Submitted by Anonymous (not verified) on 10 April 2026 - 13:53

Orphan designation: N-[(1S)-1-(4-Tert-butylphenyl) ethyl]-2-(6,7-difluoro-1H-benzimidazol-1-yl)acetamide Treatment of erythromelalgia, 23/02/2026 Positive

Link:

https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-26-3204

Source:

Newsletters

Stay informed on our latest news!

Latest Newsletters